X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3140) 3140
Publication (172) 172
Book Review (61) 61
Newsletter (56) 56
Magazine Article (32) 32
Book Chapter (17) 17
Newspaper Article (16) 16
Conference Proceeding (2) 2
Transcript (2) 2
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2670) 2670
male (1375) 1375
female (1367) 1367
digoxin (1326) 1326
digoxin - adverse effects (1120) 1120
aged (1021) 1021
digoxin - therapeutic use (912) 912
middle aged (892) 892
adult (681) 681
index medicus (650) 650
heart failure - drug therapy (557) 557
drug interactions (531) 531
pharmacology & pharmacy (529) 529
digoxin - blood (527) 527
cardiac & cardiovascular systems (470) 470
digoxin - administration & dosage (450) 450
electrocardiography (349) 349
heart failure (346) 346
animals (339) 339
atrial fibrillation - drug therapy (330) 330
mortality (291) 291
anti-arrhythmia agents - therapeutic use (261) 261
aged, 80 and over (255) 255
medicine, general & internal (252) 252
pharmacokinetics (236) 236
atrial fibrillation (234) 234
anti-arrhythmia agents - adverse effects (233) 233
digoxin - pharmacokinetics (232) 232
risk factors (217) 217
drug therapy, combination (213) 213
drug therapy (212) 212
treatment outcome (212) 212
digoxin - pharmacology (202) 202
cardiotonic agents - therapeutic use (192) 192
heart rate - drug effects (191) 191
time factors (188) 188
p-glycoprotein (180) 180
arrhythmias, cardiac - chemically induced (179) 179
cardiotonic agents - adverse effects (176) 176
management (176) 176
therapy (173) 173
dose-response relationship, drug (166) 166
digitalis (163) 163
heart failure - physiopathology (162) 162
health aspects (156) 156
adrenergic beta-antagonists - therapeutic use (155) 155
adolescent (152) 152
diuretics - therapeutic use (152) 152
digoxin - metabolism (151) 151
arrhythmias, cardiac - drug therapy (149) 149
analysis (146) 146
retrospective studies (146) 146
research (144) 144
double-blind method (141) 141
medicine & public health (140) 140
prospective studies (140) 140
care and treatment (139) 139
administration, oral (134) 134
angiotensin-converting enzyme inhibitors - therapeutic use (131) 131
toxicity (131) 131
dosage and administration (127) 127
drugs (126) 126
digitalis glycosides - adverse effects (125) 125
infant, newborn (121) 121
pregnancy (119) 119
internal medicine (117) 117
cardiac arrhythmia (115) 115
heart-failure (115) 115
age factors (114) 114
infant (114) 114
complications and side effects (113) 113
heart failure - mortality (113) 113
pharmacology/toxicology (113) 113
toxicology (112) 112
digoxin - poisoning (110) 110
risk (105) 105
clinical trials as topic (104) 104
sinus rhythm (104) 104
anti-arrhythmia agents - administration & dosage (103) 103
heart (102) 102
amiodarone (100) 100
child (100) 100
digitalis glycosides - therapeutic use (96) 96
cardiology (95) 95
cardiovascular (95) 95
cardiac patients (94) 94
chronic disease (94) 94
atrial fibrillation - physiopathology (93) 93
kinetics (92) 92
heart rate (91) 91
abridged index medicus (90) 90
drug-related side effects and adverse reactions (90) 90
follow-up studies (90) 90
trial (88) 88
hospitalization (87) 87
prognosis (87) 87
heart diseases - drug therapy (85) 85
hemodynamics - drug effects (83) 83
cross-over studies (79) 79
adverse and side effects (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2950) 2950
German (118) 118
French (46) 46
Spanish (25) 25
Italian (23) 23
Russian (21) 21
Polish (15) 15
Japanese (13) 13
Dutch (12) 12
Norwegian (7) 7
Chinese (6) 6
Danish (6) 6
Swedish (4) 4
Croatian (3) 3
Czech (3) 3
Hungarian (2) 2
Portuguese (2) 2
Afrikaans (1) 1
Finnish (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 01/2013, Volume 29, Issue 1, pp. 1 - 12
Abstract Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well... 
Rifabutin | Rifampin | Rifapentine | Drug interactions | MEDICINE, RESEARCH & EXPERIMENTAL | ENZYME-INDUCTION | PLATELET-AGGREGATION | TUBERCULOSIS | OPEN-LABEL | ATORVASTATIN | SINGLE-BLIND | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | HEALTHY-VOLUNTEERS | TRANSPORTER INHIBITION | Rifampin - analogs & derivatives | Simvastatin - therapeutic use | Antifungal Agents - adverse effects | Digoxin - adverse effects | Simvastatin - adverse effects | Antibiotics, Antitubercular - adverse effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Antifungal Agents - therapeutic use | Rifampin - adverse effects | Verapamil - therapeutic use | Drug Interactions | Verapamil - adverse effects | Rifampin - therapeutic use | Contraceptives, Oral - adverse effects | Contraceptives, Oral - therapeutic use | Digoxin - therapeutic use | HIV Protease Inhibitors - adverse effects | Rifabutin - adverse effects | Anti-Arrhythmia Agents - therapeutic use | HIV Protease Inhibitors - therapeutic use | Anticholesteremic Agents - adverse effects | Itraconazole - therapeutic use | Anticholesteremic Agents - therapeutic use | Anti-Arrhythmia Agents - adverse effects | Itraconazole - adverse effects | Antibiotics, Antitubercular - therapeutic use | Cytochrome P-450 Enzyme System - biosynthesis | Rifabutin - therapeutic use | ATP Binding Cassette Transporter, Sub-Family B
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2014, Volume 25, Issue 10, pp. 900 - 908
Abstract Background Patients with chronic diseases often receive multiple medications and are associated with increased vulnerability to medication errors.... 
Internal Medicine | Safety management/organization and administration | High-alert medications | Patient safety | Chronic patient | Medication errors/prevention and control | EMERGENCY-DEPARTMENT VISITS | HOSPITAL ADMISSIONS | UNIT | ADVERSE DRUG EVENTS | SAFETY | RISK | PREVALENCE | CARE | OLDER PERSONS | MEDICINE, GENERAL & INTERNAL | PRESCRIPTIONS | Digoxin - adverse effects | Drug-Related Side Effects and Adverse Reactions - prevention & control | Antipsychotic Agents - adverse effects | Humans | Sodium Potassium Chloride Symporter Inhibitors - adverse effects | Mineralocorticoid Receptor Antagonists - adverse effects | Amiodarone - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Amiodarone - adverse effects | Cytostatic Agents - adverse effects | Methotrexate - adverse effects | Analgesics, Opioid - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anticonvulsants - adverse effects | Anti-Arrhythmia Agents - adverse effects | Adrenergic beta-Antagonists - adverse effects | Immunosuppressive Agents - adverse effects | Benzodiazepines - adverse effects | Spironolactone - analogs & derivatives | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Spironolactone - adverse effects | Chronic Disease - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Drugs | Chronic diseases
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9985, pp. 2363 - 2370
Journal Article
Journal Article
Journal of Nephrology, ISSN 1121-8428, 12/2014, Volume 27, Issue 6, pp. 659 - 666
The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney... 
Nephrology | Phase I | Medicine & Public Health | Urology/Andrology | Hyperphosphatemia | Chronic kidney disease | Pharmacokinetics | Sucroferric oxyhydroxide | MORTALITY | PHOSPHORUS | PHOSPHATE BINDER | BIOAVAILABILITY | INDIVIDUALS | DIALYSIS PATIENTS | PA21 | CALCIUM | UROLOGY & NEPHROLOGY | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | Digoxin - adverse effects | Diuretics - pharmacokinetics | Chelating Agents - administration & dosage | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Warfarin - administration & dosage | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Cardiotonic Agents - adverse effects | Diuretics - blood | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Risk Assessment | Furosemide - pharmacokinetics | Cardiotonic Agents - pharmacokinetics | Omeprazole - administration & dosage | Sucrose - adverse effects | Anticoagulants - adverse effects | Anticoagulants - blood | Cardiotonic Agents - administration & dosage | Models, Biological | Ferric Compounds - adverse effects | Losartan - administration & dosage | Diuretics - adverse effects | Furosemide - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Anticoagulants - administration & dosage | Area Under Curve | Losartan - blood | Omeprazole - blood | Warfarin - adverse effects | Ferric Compounds - administration & dosage | Healthy Volunteers | Furosemide - adverse effects | Adult | Female | Proton Pump Inhibitors - blood | Digoxin - blood | Losartan - pharmacokinetics | Chelating Agents - adverse effects | Furosemide - blood | Sucrose - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Models, Statistical | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Proton Pump Inhibitors - pharmacokinetics | Digoxin - administration & dosage | Cardiotonic Agents - blood | Warfarin - blood | Losartan - adverse effects | Anticoagulants - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Original
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2011, Volume 27, Issue 1, pp. 47 - 59
Abstract The goals of atrial fibrillation (AF) and atrial flutter (AFL) arrhythmia management are to alleviate patient symptoms, improve patient quality of... 
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | INTRAVENOUS AMIODARONE | RENIN-ANGIOTENSIN SYSTEM | TORSADE-DE-POINTES | POLYUNSATURATED FATTY-ACIDS | FOLLOW-UP | ANTIARRHYTHMIC THERAPY | CONGESTIVE-HEART-FAILURE | VENTRICULAR RATE CONTROL | SINUS RHYTHM | ELECTRICAL CARDIOVERSION | Digoxin - adverse effects | Calcium Channel Blockers - adverse effects | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Catheter Ablation | Pacemaker, Artificial | Sotalol - therapeutic use | Dose-Response Relationship, Drug | Amiodarone - adverse effects | Heart Rate - drug effects | Sotalol - adverse effects | Amiodarone - therapeutic use | Adrenergic beta-Antagonists - adverse effects | Adult | Cardiac Output, Low - drug therapy | Drug Therapy, Combination | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Propafenone - adverse effects | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Cardiac Output, Low - complications | Amiodarone - analogs & derivatives | Flecainide - adverse effects | Canada | Myocardial Infarction - complications | Algorithms | Myocardial Infarction - drug therapy | Anti-Arrhythmia Agents - adverse effects | Atrial Fibrillation - etiology | Atrial Flutter - drug therapy | Aged | Propafenone - therapeutic use | Referral and Consultation | Flecainide - therapeutic use
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2015, Volume 36, Issue 28, pp. 1831 - 1838
Journal Article
Journal Article